A Perspective on Characterizing Benefits and Risks Derived from Clinical Trials: Can We Do More?
- 1 May 2008
- journal article
- other
- Published by Springer Nature in Drug Information Journal
- Vol. 42 (3) , 235-245
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Assessing A Structured, Quantitative Health Outcomes Approach To Drug Risk-Benefit AnalysisHealth Affairs, 2007
- Blueprint for a Stronger Food and Drug AdministrationNew England Journal of Medicine, 2006
- Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's DiseaseNew England Journal of Medicine, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- The risk of cardiovascular thrombotic events with selective cyclooxygenase‐2 inhibitorsArthritis Care & Research, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- The effects of outcome misclassification and measurement error on the design and analysis of therapeutic equivalence trialsStatistics in Medicine, 2001
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health CareMedical Care, 1994